PCSK9 and stroke disorder: Compared to placebo, PCSK9 inhibitors (alirocumab and evolocumab) reduced the risk of CVD, MI, stroke (combination of ischemic and hemorrhagic events), and all-cause death (high-certainty evidence) (for alirocumab).